tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Akero Therapeutics rumor highlighted in Betaville blog
PremiumThe FlyAkero Therapeutics rumor highlighted in Betaville blog
2M ago
Akero Therapeutics Elects New Directors at Annual Meeting
Premium
Company Announcements
Akero Therapeutics Elects New Directors at Annual Meeting
2M ago
Buy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential
Premium
Ratings
Buy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential
2M ago
Akero Therapeutics exploring potential sale after approach, Street Insider says
PremiumThe FlyAkero Therapeutics exploring potential sale after approach, Street Insider says
2M ago
Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target
Premium
Ratings
Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target
3M ago
Akero Therapeutics price target lowered to $78 from $80 at Citi
Premium
The Fly
Akero Therapeutics price target lowered to $78 from $80 at Citi
3M ago
Akero Therapeutics sees cash, equivalents funding operating plan into 2028
PremiumThe FlyAkero Therapeutics sees cash, equivalents funding operating plan into 2028
3M ago
Promising Phase 2b Results for Akero Therapeutics’ Efruxifermin Highlight Potential for FDA Approval Despite Key Risk Score Challenges
Premium
Ratings
Promising Phase 2b Results for Akero Therapeutics’ Efruxifermin Highlight Potential for FDA Approval Despite Key Risk Score Challenges
3M ago
Promising Phase 2b Results and Future Prospects for Akero Therapeutics’ Efruxifermin Boost Buy Rating
Premium
Ratings
Promising Phase 2b Results and Future Prospects for Akero Therapeutics’ Efruxifermin Boost Buy Rating
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100